US FDA panel backs claim Lilly diabetes drug - (Channel News Asia via NewsPoints Desk)

  • An FDA advisory panel was split regarding whether to permit Eli Lilly and Boehringer Ingelheim to add data the label of the diabetes drug Jardiance indicating its productive effect against cardiac death, as reported Channel News Asia Tuesday.

  • Specifically, the committee voted 12-11 in favour of letting the drugmakers to state on the Jardiance label that the therapy reduces cardiovascular risk.

  • The panel unanimously agreed that the drug does not increase cardiovascular risk.

To read more NewsPoints articles, click here.

Reference Articles